Myriad Genetics Inc. will return for a repeat engagement of its Phase I collaboration with Biomarin Pharmaceuticals Inc. to deliver BRAC testing for Biomarin’s pivotal Phase III trials of BMN 673. BMN 673 is an oral poly ADP-ribose polymerase (PARP) inhibitor designed to kill BRCA-deficient cancer cells.
Tetraphase Pharmaceuticals Inc., of Watertown, Mass., shared the design of its planned Phase III trial of eravacycline for complicated urinary tract infections (cUTI), due to begin enrolling in late 2013.
Riding high on recent positive Phase III data for its hyperkalemia candidate, Relypsa Inc. filed for a $126.5 million initial public offering (IPO) to ramp up commercial operations for launch of patiromer, which is designed to remove potassium in the colon.
Inotek Pharmaceuticals Corp., of Lexington, Mass., plans to apply $21 million in proceeds from a venture financing and $7 million in venture debt financing to advance its A1 subtype adenosine mimetic for glaucoma and ocular hypertension. The funds will allow it to begin a Phase II study of trabodenoson in combination with latanoprost in late 2013.
People with Duchenne muscular dystrophy (DMD) have gained a powerful new ally in CureDuchenne Ventures, a nonprofit organization dedicated to funding drug discovery and development for the rare disease.
An anxious wait for Oncothyreon Inc. has come to an end, as Merck KGaA announced it would continue development of tecemotide (formerly Stimuvax) following last year’s Phase III trial miss.
X-Chem Inc., of Waltham, Mass., said it achieved several milestones in a licensing agreement with Astrazeneca plc, of London, established in May 2012. That deal garnered the company an up-front payment and research funding, as well as discovery and clinical development milestones.
A Phase III trial of Achaogen Inc.’s plazomicin for serious multidrug-resistant gram-negative bacterial infections will be carried out through a special protocol assessment (SPA) under a new agreement with the FDA. The trial will assess safety and efficacy of the drug compared with colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE).
